| Identification | Back Directory | [Name]
Pyrazinecarboxamide, 6-fluoro-3,4-dihydro-3-oxo- (9CI) | [CAS]
259793-96-9 | [Synonyms]
T-705
T-705,T705
Favipiravi
Favipiravjr
Favipiravir
Unii-ew5gl2X7E0
Favipiravir API
T-705 favipiravir
Favipiravir(T-705)
favipiravir USP/EP/BP
The method of villa wei
PyrazinecarboxaMide, 6-fl...
T 705; FAVIPIRAVIR;T-705;T705
6-fluoro-3,4-dihydro-3-oxo- (9CI)
6-Fluoro-3-hydroxypyrazine-2-carboxamide
5-fluoro-2-oxo-1H-pyrazine-3-carboxamide
6-Fluoro-3-hydroxy-2-pyrazinecarboxamide
6-fluoro-3,4-dihydro-3-oxo-Pyrazinecarboxamide
PYRAZINECARBOXAMIDE, 6-FLUORO-3,4-DIHYDRO-3-OXO-
6-Fluoro-3-oxo-3,4-dihydropyrazine-2-carboxaMide
6-Fluoro-3,4-dihydro-3-oxo-2-pyrazinecarboxamide
6-Fluoro-3,4-dihydro-3-oxo-pyrazinecarboxaMide 95%
2-PyrazinecarboxaMide, 6-fluoro-3,4-dihydro-3-oxo-
6-Fluoro-3-hydroxypyrazine-2-carboxamide
favipiravir
favipiravir 6-fluoro-3-hydroxypyrazine-2-carboxamide
Favipiravir (This product is unavailable in the U.S.)
Pyrazinecarboxamide, 6-fluoro-3,4-dihydro-3-oxo- (9CI) | [EINECS(EC#)]
1533716-785-6 | [Molecular Formula]
C5H4FN3O2 | [MDL Number]
MFCD12032148 | [MOL File]
259793-96-9.mol | [Molecular Weight]
157.103 |
| Chemical Properties | Back Directory | [Melting point ]
>151°C (dec.) | [density ]
1.78±0.1 g/cm3(Predicted) | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
Soluble in DMSO (30 mg/mL), water (12 mg/mL with warming) | [form ]
solid | [pka]
8.77±0.60(Predicted) | [color ]
Off-white | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or water may be stored at -20° for up to 3 months. |
| Hazard Information | Back Directory | [Description]
Favipiravir, 6-fluoro-3-hydroxypyrazine-2-carboxamide, is a new broad-spectrum antiviral drug targeting RNA-dependent RNA polymerase (RdRp) developed by Japan's Toyama Chemical Pharmaceutical Company. It was approved for marketing in Japan in March 2014 for the treatment of new and recurrent influenza. During the outbreak of the new coronavirus, the results of the Phase I clinical study of the drug published in March 2020 showed that the drug may have the effect of speeding up virus clearance to alleviate the progress of new coronavirus pneumonia. | [History]
Favipiravir was originally developed in the late 1990s by a company that was later purchased by the Japanese firm Fujifilm as part of its transition from the photo business to healthcare. After being tested against a range of viruses, the drug was approved in Japan in 2014 for emergency use against flu epidemics or to treat new strains of influenza. | [Uses]
Favipiravir can be used for antiviral treatment of influenza A and B. Studies have shown that in addition to influenza virus, the drug also exhibits good antiviral activity against a variety of RNA viruses, such as Ebola virus, arena virus, Bunia virus, and rabies virus. | [Definition]
ChEBI: Favipiravir is a member of the class of pyrazines that is pyrazine substituted by aminocarbonyl, hydroxy and fluoro groups at positions 2, 3 and 6, respectively. It is an anti-viral agent that inhibits RNA-dependent RNA polymerase of several RNA viruses and is approved for the treatment of influenza in Japan. It has a role as an antiviral drug, an anticoronaviral agent and an EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor. It is a primary carboxamide, a hydroxypyrazine and an organofluorine compound. | [Mechanism of action]
Favipiravir is an antiviral drug that selectively inhibited the RdRP of influenza virus. It showed specific activity against all three influenza A, B, and C (Furuta et al., 2013). It also inhibited the RV replication in HeLa cells, with an EC50 of 29 μg/mL (Furuta et al., 2002). Analysis showed that the primary mechanism of action of favipiravir against the influenza virus was specific inhibition of vRNA polymerase (Furuta et al., 2005). It is predicted that a similar mechanism might occur with other viruses, such as PV and RV, inhibited by favipiravir, which may account for its broad-spectrum inhibition. Mechanistic studies show that the favipiravir and its form favipiravir-RMP (favipiravir-ribofuranosyl-50-monophosphate) do not inhibit influenza RNA polymerase activity, but it is the phosphoribosylated form, favipiravir-ribofuranosyl-50-triphosphate (RTP) that inhibits the enzyme. | [Synthesis]
645 grams of sodium hydroxide were dissolved in 9L of water, the temperature was lowered to 5°C, and 1.29 kg of 6-fluoro-3-hydroxy-2-cyanopyrazine was added in batches, stirred, and heated slightly, and the temperature of the reaction system was controlled to -10°C, it takes 3.5 hours to complete the addition, after holding for 1 hour, the temperature is raised to 40°C for 1 hour. Add 100g of activated carbon to the reaction solution, hot filter, cool the mother liquor to 5°C, adjust the pH to 3-4 with concentrated hydrochloric acid, precipitate a large amount of solids, filter and dry to obtain a crude off-white powder, beaten with 2.8 liters of 15% methanol aqueous solution and filter After drying, 1.34 kg of white powder favipiravir was obtained. 1H-NMR (DMSO, 600MHz): δ 13.38 (s, 1H), 8.73 (1s, 1H), 8.51-8.49 (d, J=12, 2H) (yield 91%).
| [storage]
Store at -20°C | [References]
1) Furuta?et al.?(2002),?In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705; Antimicrob. Agents Chemother.,?46?977
2) Takahashi?et al.?(2003)?In Vitro and In Vivo Activities of T-705 and Oseltamivir Against Influenza Virus; Antivir. Chem. Chemother.,?14?235
3) Sleeman?et al.?(2010)?In Vitro Antiviral Activity of Favipiravir (T-705) against Drug-Resistant Influenza and 2009 A(H1N1) Viruses; Antimicrob. Agents Chemother.,?54?2517
4) Furuta?et al.?(2005)?Mechanism of action of T-705 against influenza virus; Antimicrob. Agents Chemother.,?49?981
5) Furuta?et al.?(2013)?), Favipiravir (T-705), a Novel Viral RNA Polymerase Inhibitor; Antiviral Res.,?100?446
6) Dong?et al.?(2020)?Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19); Drug Discov. Ther.,?14?58
7) Tu?et al.?(2020)?A Review of SARS-CoV-2 and the Ongoing Clinical Trials; Int. J. Mol. Sci., 21?E2657 |
|
|